Alexza Pharma Shares Moving Higher as Co. Wins Marketing Authorization for ADASUVE in EU

Alexza Pharmaceuticals, Inc.

and Grupo Ferrer Internacional, S.A., today announced that the European Commission has granted marketing authorization for ADASUVE ( Staccato loxapine).  In the European Union (EU), ADASUVE, 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.   The ADASUVE marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that ADASUVE is administered only in a hospital setting under the supervision of a healthcare professional.  Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects (bronchospasm).